Molecular imaging developer Gamma Medica has secured new capital financing.
The financing came from Hercules Technology Growth Capital, which invested $6.5 million, while $5 million came from current investor Psilos Group.
Gamma Medica plans to use the funding to accelerate sales and marketing efforts and promote the adoption of its molecular breast imaging (MBI) technology.
Gamma Medica's LumaGem MBI system is designed for women with complex breast anatomy, such as dense breast tissue, where screening mammograms and ultrasound scans may miss early cancers. LumaGem has been cleared by the U.S. Food and Drug Administration (FDA).
